CVS Caremark Corp. has appointed Dr. Alan Lotvin executive vice president of specialty ­pharmacy.


CVS Caremark, Alan Lotvin, specialty pharmacy, pharmacy benefit management, Jon Roberts, PBM, specialty pharmacy leadership, specialty pharmacy services, Medco






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Inside This Issue - News

CVS names exec to lead specialty Rx

November 5th, 2012

WOONSOCKET, R.I. – CVS Caremark Corp. has appointed Dr. Alan Lotvin executive vice president of specialty ­pharmacy.

In this role Lotvin, who is a cardiologist with extensive experience in pharmacy benefit management and specialty pharmacy, will have overall responsibility for the company’s specialty pharmacy strategy, with a focus on identifying opportunities for growth and ­innovation.

“Specialty pharmacy is an increasingly important growth area for CVS Caremark, and Alan’s in-depth experience and knowledge of the industry make him uniquely qualified to lead this portion of our business,” notes Jon Roberts, president of the CVS Caremark PBM business.
“His expertise will enable us to continue to grow our specialty pharmacy leadership and identify opportunities for ongoing innovation to enable us to better help patients dealing with complex, debilitating diseases.”

Prior to joining CVS Caremark, Lotvin was president and chief executive officer of Magellan Health Services Inc.’s ICORE Healthcare unit.

Earlier in his career he held positions at the medical education provider M/C Communications and at Medco Health Solutions, including president of the company’s specialty pharmacy services business.

“I am looking forward to working with the team at CVS Caremark to continue to grow and build upon the company’s specialty pharmacy offerings,” Lotvin says. “With specialty drugs estimated to account for seven of the top 10 drugs in the United States by 2016, we need to continue to develop programs and solutions that will help our clients improve outcomes for these complicated diseases while managing cost and ensuring appropriate utilization.”

Advertisement